Aardvark Therapeutics company information, Employees & Contact Information

Aardvark (Nasdaq: AARD) sets Nov 5 investor webinar on ObesityWeek 2025 pipeline data Stock Titan

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek The Manila Times

Aardvark Therapeutics, Inc. Announces Key Leadership Appointments to Enhance Scientific, Commercial, and Regulatory Expertise Nasdaq

Insider Stock Buying Reaches US$730.4k On Aardvark Therapeutics Yahoo Finance

Aardvark Therapeutics Aligns with FDA on Trial Amendment TipRanks

Aardvark Therapeutics Stock (AARD) Opinions on Insider Trading and Clinical Trials Quiver Quantitative

Phase 3 HERO Expanded to Ages 10+ — Aardvark Aligns with FDA on ARD-101 Trial; Readout Q3 2026 Stock Titan

San Diego’s Aardvark Therapeutics Nets $94 Million in IPO Fred Grier | Substack

Aardvark Therapeutics Appoints Renowned Biopharma Leaders Roy D. Baynes and Susan E. Graf to its Board of Directors Business Wire

Obesity-Focused Aardvark Therapeutics Files IPO to Advance Lead Candidate BioSpace

Aardvark prices $94M IPO to fund Prader-Willi, obesity drug work BioPharma Dive

Jones Trading Initiates Coverage of Aardvark Therapeutics (AARD) with Buy Recommendation Nasdaq

Aardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash MedCity News

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments (AARD) Seeking Alpha

Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet Yahoo Finance

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome The Manila Times

Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut Fierce Biotech

Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments BioSpace

Is Aardvark Therapeutics Inc. stock ready for breakout - July 2025 Institutional & Daily Risk Controlled Trade Plans Trung tâm Dự báo KTTV quốc gia

Aardvark Therapeutics Rings the Closing Bell Nasdaq

Aardvark therapeutics CEO Lee Tien-Li buys $160k in AARD Investing.com

Is Aardvark Therapeutics Inc. stock ready for breakout - 2025 Market WrapUp & Safe Entry Trade Reports Trung tâm Dự báo KTTV quốc gia

Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) stock price dropped 11% last week; individual investors would not be happy simplywall.st

Insiders Rewarded With US$275k Addition To Investment As Aardvark Therapeutics Stock Hits US$349m simplywall.st

Why Aardvark Therapeutics Inc. stock appeals to analysts - Portfolio Value Report & Real-Time Market Sentiment Reports Trung tâm Dự báo KTTV quốc gia

Aardvark Therapeutics Updates Corporate Presentation on Strategy TipRanks

Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock Investing.com

H.C. Wainwright reiterates Buy rating on Aardvark Therapeutics stock Investing.com

Aardvark therapeutics CEO Lee Tien-Li buys $96,623 in shares Investing.com

Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study TipRanks

Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock Investing.com

H.C. Wainwright initiates coverage on Aardvark Therapeutics stock with Buy rating Investing.com

Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment Insider Monkey

Aardvark Therapeutics Raises $85M Series C Funding Round Fred Grier | Substack

Big Moves: Major Stakeholders Invest Heavily in Aardvark Therapeutics TipRanks

Aardvark heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials Fierce Biotech

Insiders Of Aardvark Therapeutics Reap Rewards After Their Investment Jumps Another US$275k 富途牛牛

Aardvark Therapeutics Completes $85 Million Oversubscribed Series C Round of Funding, Aiming to Advance ARD-101 for Hyperphagia in Patients with Prader-Willi Syndrome Pharmaceutical Executive

Aardvark Therapeutics Announces $85M Series C Financing Contract Pharma

Aardvark Therapeutics announces positive data from ARD-101 trials Clinical Trials Arena

Bitter Taste Receptors Represent a Therapeutic Sweet Spot Genetic Engineering and Biotechnology News